{"groups":[{"description":"Mifepristone was administered at doses of 300-1200 mg daily.","id":"FG000","title":"Mifepristone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Subject was too ill to travel."},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Subject was non-compliant."}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"50"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"34"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"16"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Adults with endogenous Cushing's Syndrome associated with either type 2 diabetes mellitus/impaired glucose tolerance or a diagnosis of hypertension.","recruitmentDetails":"24 week multicenter, open-label trial after failed multimodality therapy at 14 U.S. academic medical centers and three private research centers."}